Topics

AstraZeneca's Phase III POSEIDON Trial Meets Primary Endpoint

17:52 EDT 28 Oct 2019 | FinanzNachrichten

LONDON (dpa-AFX) - AstraZeneca plc (AZN) Monday announced positive progression-free survival results for IMFINZI and tremelimumab, an anti-CTLA-4 antibody, when added to chemotherapy, from the Pha...

Original Article: AstraZeneca's Phase III POSEIDON Trial Meets Primary Endpoint

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Phase III POSEIDON Trial Meets Primary Endpoint"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...